BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …

The innate immune pathways induced by adjuvants required to increase adaptive
responses to influenza subunit vaccines are not well characterized. We profiled different …

Background: Children have high morbidity and hospitalization rates from seasonal
influenza. Meta-analyses suggest that conventional inactivated influenza vaccines are of low …

The ISCOMATRIX adjuvant has antigen delivery and presentation properties as well as
immunomodulatory capabilities, which combine to provide enhanced and accelerated …

Inflammasomes have emerged as context-dependent regulators of inflammation and
protective immunity in vertebrates. Depending on the cell type and stimulus, inflammasome …

Studying the spread of influenza in human populations and protection by influenza vaccines
provides important insights into immunity against influenza. The 2009 H1N1 pandemic has …

A major challenge for current vaccine development is the fact that many new subunit
vaccines based on highly purified recombinant proteins are poorly immunogenic and …

Influenza is an important contributor to morbidity and mortality worldwide. Accumulation of
genetic mutations termed antigenic drift, allows influenza viruses to inflict yearly epidemics …

Background Pathogenic avian influenza virus (H5N1) has the potential to cause a major
global pandemic in humans. Safe and effective vaccines that induce immunologic memory …

MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for
more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad® …